DS
NEOS

David Shaw’s Neos Therapeutics, Inc NEOS Stock Holding History

David Shaw’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-18,653
Closed -$28K – 4256
2019
Q3 		$28K Sell
18,653
-25,253
-58% -$40.9K ﹤0.01% 3751
2019
Q2 		$57K Buy
+43,906
New +$80.8K ﹤0.01% 3582

Other funds holding NEOS

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

David Shaw's NEOS Position: Q4 2019 in Review

David Shaw sold out of Neos Therapeutics, Inc (NEOS) in Q4 2019, closing a stake of 18,653 shares — an estimated $28K sold.

David Shaw first reported a position in NEOS in Q2 2019 and held it in 2 quarters. The position peaked at $57K in Q2 2019. 54 funds tracked by Wall St. Rank hold NEOS as of Q4 2019.

  • David Shaw reported no remaining Neos Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • David Shaw sold 18,653 Neos Therapeutics, Inc shares in Q4 2019, an estimated $28K.
  • David Shaw first reported a position in Neos Therapeutics, Inc in Q2 2019 and held it in 2 quarters.
  • David Shaw's Neos Therapeutics, Inc position peaked at $57K in Q2 2019.
  • 54 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q4 2019.

Based on D.E. Shaw & Co's 13F filing for Q4 2019, filed 14 Feb 2020.